Automated Compounding Devices (ACD) Market

Market Overview:

The Automated Compounding Devices (ACD) Market is anticipated to exhibit substantial growth with a high CAGR during the forecast period 2023-2030. These innovative machines, utilized primarily in healthcare settings such as pharmacies and hospitals, are revolutionizing drug manufacturing, ensuring accurate and sterile formulations.

Market Dynamics:

Drivers:

Technological Advancements: Continuous improvements in Automated Compounding Devices (ACDs) aim to enhance patient safety, streamline pharmacy operations, and meet evolving healthcare needs. Recent launches like the ExactaMix Pro Automated Compounder and IVX Station are examples of technological advancements enhancing features and processing power.
Challenges:

Drug Shortages: In some cases, ACDs reliant on pre-filled drug vials or cartridges may compound drug shortages, impacting the compounding process.
Segment Analysis:

The market is segmented based on product type, technology, component, mode of operation, end-user, and region. The Intravenous (IV) compounding systems segment holds a significant share (approximately 39.7%) due to their critical role in patient safety and streamlined drug compounding procedures.

Request For Free Sample:
https://www.datamintelligence.com/download-sample/automated-compounding-devices-market

Geographical Share:

North America:

Dominance due to the presence of major pharmaceutical industries and a healthcare system dedicated to patient safety. The United States' early adoption of medical technology contributes to the widespread acceptance and use of ACDs in healthcare settings.

COVID-19 Impact:
The pandemic accentuated the importance of sterile compounding, especially for drugs used in critical care. ACDs, known for their sterility and precision, played a crucial role in meeting this increased demand. The focus on pharmaceutical safety during the pandemic highlighted the significance of ACDs in reducing medication errors.

Key Companies:
Major global players include Grifols, S.A, Baxter International Inc, COMECER S.p.A., ARxIUM, ICU Medical, Inc, Omnicell, Inc, EQUASHIELD, B. Braun Medical Inc., BECTON, DICKINSON AND COMPANY, SMARTCOMPOUNDERS B.V., among others.

Key Developments:
December 2022 will see the introduction of the APEX Compounding System and its exclusive TPN Manager Clinical Decision Support Order Entry Software by B. Braun Medical Inc., designed to meet critical conditions' urgent needs across all age groups.
The market's growth trajectory is propelled by technological advancements, the critical role of IV compounding systems in patient safety, and the focus on pharmaceutical precision highlighted during the COVID-19 pandemic. However, challenges related to drug shortages and initial costs of ACDs may impede market growth to some extent.

Related Reports:

https://www.datamintelligence.com/research-report/automated-insulin-delivery-systems-market
https://www.datamintelligence.com/download-sample/asthma-and-copd-devices-market
https://www.datamintelligence.com/download-sample/cell-counting-devices-market

Media Contact
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele

This release was published on openPR.